Enlivex Receives Regulatory Approval for TMJ Osteoarthritis Trial at Sheba Medical Center
“TMJ osteoarthritis is a unique disease that can affect young, otherwise healthy individuals, causing substantial pain and impairment in oral function,” states Dr. Oren Hershkovitz, CEO of Enlivex Therapeutics. “In many cases, existing therapies fail to provide long-term relief, forcing patients to undergo multiple surgeries as their disease progresses.”
Trial Design and Evaluation
Allocetra represents an important advancement in cell therapy development. This universal, off-the-shelf cell therapy works by resetting immune cells called macrophages back to their natural balanced state. When these immune cells become disrupted – as commonly seen in conditions like sepsis and solid cancers – they can worsen disease progression and severity.
The treatment’s innovative approach to restoring normal immune cell function presents a new therapeutic option for serious conditions that currently lack effective treatments. This could be particularly valuable for TMJ osteoarthritis patients, where both soft and hard tissues in the jaw joint deteriorate over time.
Clinical Development Context
The initiation of this trial follows Enlivex’s recent success in April, where the company reported positive topline safety and efficacy data from a Phase II trial of Allocetra in sepsis patients. This expansion into TMJ osteoarthritis represents a strategic broadening of the therapy’s potential applications.
More Posts
Sheba’s Prof. Amitai Ziv Awarded by IMSH for Medical Simulation Excellence
Prof. Amitai Ziv, Founder of MSR-Azrieli Medical Simulation Center and Director of the Rehabilitation Hospital at Sheba Medical Center, has received...
Sheba’s Physicians Sweep Forbes Israel’s 2025 “Best Doctors” List
Forbes Israel has named an exceptional number of Sheba Medical Center’s physicians on its 2025 “Best Doctors” list. Earlier this year, Sheba was ranked by Newsweek as one of the World’s Top 10 Hospitals. This recognition and alignment between institutional and individual excellence signals to the global medical community that Sheba concentrates many of Israel’s most trusted clinical leaders under one roof.
Twinning and Training: Scalable Solutions for Global Eye Cancer Equity
Sheba Global Ophthalmology (SGO) demonstrates how sustainable twinning and hands-on training create self-reliant ocular oncology capacity in low- and middle-income countries (LMICs), far surpassing the limitations of short-term outreach.
